Cencora, Inc.

COR · NYSE · USD

Can Cencora keep profit growing faster than revenue as manufacturer price cuts, biosimilar in-sourcing and customer losses shrink the top line?

Last 4 earnings calls · through Q3 FY2026

Bull case

  • Specialty mix lifts profit

    The bull case is that specialty pharmaceuticals and the physician practices Cencora now owns carry higher margins than the plain distribution business they replace.

  • Pricing holds through price cuts

    Cencora renegotiates with manufacturers whenever list prices fall and has kept its gross profit dollars, so revenue declines do not automatically reach operating income.

  • Cash funds the build-out

    Cash generation pays for the distribution network, the practice acquisitions and the buyback, so growth does not depend on issuing new shares or on borrowing more.

Bear case

  • Revenue growth is slowing

    The bear case is that price cuts and faster brand-to-biosimilar switching keep shrinking reported revenue, and management has already cut its revenue outlook once.

  • Customer losses hit the base

    Cencora lost an oncology customer to a rival acquisition, off-boarded a grocery customer, and is seeing volume move in-house at its largest mail order customer.

  • Acquisitions add debt

    The practice acquisitions were funded with borrowed money, raising interest costs, and a large distribution build-out is committed before the returns show up.

  • Federal drug pricing rules

    The bear case is that Medicare price negotiation and reimbursement rules are decided outside the company, so the timing and size of the cost cannot be planned.

Bull and bear points

Growth & Execution

In short: Specialty practices and MSOs grow fast, while price cuts and customer losses hold down reported revenue.

Bull · 2

  • OneOncology closes early and beats plan

    A year ago management had only a pathway to full ownership; it has now closed the deal and says the platform is performing above its purchase case.

    Tone shiftQ4 FY2025 → Q3 FY2026

  • Core U.S. profit grows double digits before MSOs

    Excluding OneOncology and the oncology customer that was lost, U.S. operating income still grew at a double-digit rate, which says the base distribution business is not leaning on acquisitions to expand.

    Q3 FY2026 call
Bear · 2

  • Revenue growth guidance cut to 4% to 6%

    In February management raised full-year revenue growth guidance to 7% to 9%; in May it cut the range to 4% to 6%, citing faster brand-to-biosimilar switching at a mail order customer and slower GLP-1 growth.

    Tone shiftQ1 FY2026 → Q2 FY2026

  • GLP-1 sales growth slower than planned

    Part of the revenue outlook cut comes from GLP-1 growth decelerating, and management says a five-point change in that class's growth is worth about $2 billion of annual revenue, so the swing is large.

    Q2 FY2026 call

Profitability & Financial Strength

In short: Operating income grows faster than revenue, while acquisition debt has lifted interest expense.

Bull · 2

  • Gross margin expands on MSO mix

    Gross margin rose to 4.3% from 3.6% a year earlier as practice-management services and specialty fees took a larger share, and on such a thin base even small mix shifts move operating profit.

    Filed financials

  • Buybacks restart after debt paydown

    Buybacks were paused to pay down acquisition debt and have now resumed, with $1 billion repurchased in the June quarter and a lower share count supporting earnings per share without extra profit.

    Tone shiftQ1 FY2026 → Q2 FY2026
Bear · 2

  • Acquisition debt raises interest costs

    Net debt is $8.9 billion against $6.0 billion a year earlier, and management expects net interest expense near $490 million this year, which takes cash that would otherwise fund buybacks or deals.

    Q3 FY2026 call

  • Capital spending steps up before returns

    Trailing capital spending is up 27% to $761 million, and management plans about $900 million this fiscal year on distribution centers and technology, so cash flow carries a heavier bill first.

    Q4 FY2025 call

Market Position

In short: Cencora defends its distribution pricing, but a few large customers and federal policy can shift volume.

Bull · 2

  • Price-cut talks protect gross profit dollars

    When manufacturers cut list prices after Medicare negotiation, Cencora renegotiates and says it preserved its gross profit dollars, which is the real test of whether its distribution work still commands payment.

    Q1 FY2026 call

  • Part B biosimilar switches add profit

    In buy-and-bill settings where Cencora provides distribution, group purchasing and practice services, a brand-to-biosimilar switch enlarges its role and its profit, unlike mail-order Part D where volume can move in-house.

    Q3 FY2026 call
Bear · 2

  • Large customers keep moving volume

    An oncology customer was acquired by a peer, a grocery customer was off-boarded, and the largest mail order customer converted brands to biosimilars faster than expected, each removing revenue Cencora had counted on.

    Q2 FY2026 call

  • 340B and ASP rules remain unresolved

    Management says new 340B guidance is still being assessed and will not size it, and proposed payment-rule changes are still being watched, so the policy cost to distribution and practice economics is unknown.

    Q3 FY2026 call